Recognition Functions of Pentameric C-Reactive Protein in Cardiovascular Disease

被引:28
作者
Agrawal, Alok [1 ]
Gang, Toh B. [1 ]
Rusinol, Antonio E. [1 ]
机构
[1] E Tennessee State Univ, Quillen Dishner Coll Med, Dept Biomed Sci, Johnson City, TN 37614 USA
关键词
LOW-DENSITY-LIPOPROTEIN; FOAM-CELL-FORMATION; ATHEROSCLEROTIC LESIONS; APOPTOTIC CELLS; IMMUNOHISTOCHEMICAL LOCALIZATION; INFARCT SIZE; OXIDIZED LDL; COMPLEMENT; BINDING; MACROPHAGES;
D O I
10.1155/2014/319215
中图分类号
Q2 [细胞生物学];
学科分类号
071009 ; 090102 ;
摘要
C-reactive protein (CRP) performs two recognition functions that are relevant to cardiovascular disease. First, in its native pentameric conformation, CRP recognizes molecules and cells with exposed phosphocholine (PCh) groups, such as microbial pathogens and damaged cells. PCh-containing ligand-bound CRP activates the complement system to destroy the ligand. Thus, the PCh-binding function of CRP is defensive if it occurs on foreign pathogens because it results in the killing of the pathogen via complement activation. On the other hand, the PCh-binding function of CRP is detrimental if it occurs on injured host cells because it causes more damage to the tissue via complement activation; this is how CRP worsens acute myocardial infarction and ischemia/reperfusion injury. Second, in its nonnative pentameric conformation, CRP also recognizes atherogenic low-density lipoprotein (LDL). Recent data suggest that the LDL-binding function of CRP is beneficial because it prevents formation of macrophage foam cells, attenuates inflammatory effects of LDL, inhibits LDL oxidation, and reduces proatherogenic effects of macrophages, raising the possibility that nonnative CRP may show atheroprotective effects in experimental animals. In conclusion, temporarily inhibiting the PCh-binding function of CRP along with facilitating localized presence of nonnative pentameric CRP could be a promising approach to treat atherosclerosis and myocardial infarction. There is no need to stop the biosynthesis of CRP.
引用
收藏
页数:6
相关论文
共 91 条
  • [1] CRP after 2004
    Agrawal, A
    [J]. MOLECULAR IMMUNOLOGY, 2005, 42 (08) : 927 - 930
  • [2] Not only immunoglobulins, C-reactive protein too
    Agrawal, Alok
    [J]. MOLECULAR IMMUNOLOGY, 2013, 56 (04) : 561 - 562
  • [3] Agrawal Alok, 2010, Cardiovascular & Hematological Disorders - Drug Targets, V10, P235
  • [4] Agrawal Alok, 2008, Endocrine Metabolic & Immune Disorders-Drug Targets, V8, P231, DOI 10.2174/187153008786848321
  • [5] C-reactive protein is a bystander of cardiovascular disease
    Anand, Sonia S.
    Yusuf, Salim
    [J]. EUROPEAN HEART JOURNAL, 2010, 31 (17) : 2092 - U25
  • [6] C-reactive-protein-associated increase in myocardial infarct size after ischemia/reperfusion
    Barrett, TD
    Hennan, JK
    Marks, RM
    Lucchesi, BR
    [J]. JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS, 2002, 303 (03) : 1007 - 1013
  • [7] Complement and atherogenesis - Binding of CRP to degraded, nonoxidized LDL enhances complement activation
    Bhakdi, S
    Torzewski, M
    Klouche, M
    Hemmes, M
    [J]. ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY, 1999, 19 (10) : 2348 - 2354
  • [8] Modified low density lipoproteins differentially bind and activate the C1 complex of complement
    Biro, Adrienn
    Thielens, Nicole M.
    Cervenak, Laszlo
    Prohaszka, Zoltan
    Fust, George
    Arlaud, Gerard J.
    [J]. MOLECULAR IMMUNOLOGY, 2007, 44 (06) : 1169 - 1177
  • [9] The pro-atherogenic effects of macrophages are reduced upon formation of a complex between C-reactive protein and lysophosphatidylcholine
    Chang, Mi-Kyung
    Hartvigsen, Karsten
    Ryu, Jewon
    Kim, Yuna
    Han, Ki Hoon
    [J]. JOURNAL OF INFLAMMATION-LONDON, 2012, 9
  • [10] C-reactive protein binds to both oxidized LDL and apoptotic cells through recognition of a common ligand: Phosphorylcholine of oxidized phospholipids
    Chang, MK
    Binder, CJ
    Torzewski, M
    Witztum, JL
    [J]. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2002, 99 (20) : 13043 - 13048